Yang Qing, Liu Guiqun, Guo Min, Yuan Dunlu, Huang Jingjing, Zhou Zhu, Li Qing
Department of Nephrology, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Department of Otolaryngology, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Kidney Dis (Basel). 2025 Mar 29;11(1):270-282. doi: 10.1159/000545262. eCollection 2025 Jan-Dec.
The aim of the study was to assess the impact of employing the KHA-200 hemoperfusion device in conjunction with hemodialysis therapy in the elimination of serum solutes among maintenance hemodialysis (MHD) patients.
A total of ninety-two MHD patients from our hospital's hemodialysis center were judiciously chosen and allocated randomly into two groups: the conventional hemodialysis group, serving as the control group, and the group utilizing the KHA-200 hemoperfusion device in combination with hemodialysis, denoted as the experimental group, in a 1:1 ratio. We compared variations in serum solute indices, including blood urea nitrogen, creatinine, potassium, calcium, phosphorus, high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), β2-microglobulin (β2-MG), parathyroid hormone (PTH), homocysteine (Hcy), albumin, both prior to and post-treatment. Meanwhile, a comparison of the serum solute clearance rates in the two groups was performed.
Following treatment, both groups exhibited substantial reductions in blood urea nitrogen, creatinine, uric acid, potassium, phosphorus, PTH, and Hcy ( < 0.001). There were no statistically significant distinctions between the two groups in terms of urea nitrogen, creatinine, uric acid, and potassium clearance ( > 0.05). Conversely, the experimental group demonstrated a significant effect on the elimination of IL-6 and β2-MG ( < 0.001). Furthermore, the experimental group's performance in reducing blood phosphorus, PTH, IL-6, β2-MG, and Hcy was significantly superior to that of the control group ( < 0.05). Moreover, the reduction in systolic blood pressure in the experimental group was better than in the control group.
Employing the KHA-200 hemoperfusion device in tandem with hemodialysis excels in removing blood phosphorus and certain medium-sized uremic toxins, including PTH, IL-6, β2-MG, and Hcy, surpassing the performance of conventional hemodialysis.
本研究的目的是评估在维持性血液透析（MHD）患者中使用KHA - 200血液灌流装置联合血液透析治疗对血清溶质清除的影响。
从我院血液透析中心精心挑选92例MHD患者，并随机分为两组：传统血液透析组作为对照组，以及使用KHA - 200血液灌流装置联合血液透析的组作为实验组，比例为1:1。我们比较了治疗前后血清溶质指标的变化，包括血尿素氮、肌酐、钾、钙、磷、高敏C反应蛋白（hsCRP）、白细胞介素 - 6（IL - 6）、β2 - 微球蛋白（β2 - MG）、甲状旁腺激素（PTH）、同型半胱氨酸（Hcy）、白蛋白。同时，对两组的血清溶质清除率进行了比较。
治疗后，两组患者的血尿素氮、肌酐、尿酸、钾、磷、PTH和Hcy均显著降低（<0.001）。两组在尿素氮、肌酐、尿酸和钾清除方面无统计学显著差异（>0.05）。相反，实验组对IL - 6和β2 - MG的清除有显著效果（<0.001）。此外，实验组在降低血磷、PTH、IL - 6、β2 - MG和Hcy方面的表现明显优于对照组（<0.05）。而且，实验组收缩压的降低情况优于对照组。
将KHA - 200血液灌流装置与血液透析联合使用在清除血磷和某些中分子尿毒症毒素（包括PTH、IL - 6、β2 - MG和Hcy）方面表现出色，优于传统血液透析。
